Seeking Alpha

Isis Pharmaceuticals (ISIS +2%) says it will receive $1.1M from Alnylam Pharmaceuticals (ALNY...

Isis Pharmaceuticals (ISIS +2%) says it will receive $1.1M from Alnylam Pharmaceuticals (ALNY +0.2%) as its portion of the upfront fees in ALNY's recently announced collaboration with Genzyme. In addition, Isis has the potential to receive royalty payments and a portion of future milestone payments. Already this year, Isis has earned $2.7M from Alnylam as a result of licenses that were supported by Isis' patents.
From other sites
Comments (1)
  • horseman
    , contributor
    Comments (203) | Send Message
     
    Well, sounds nice, but, Is ISIS really going to make THE GRADE (like A+) in the next decade! My history with this company goes back 15 years or so and I really haven't seen much bottom line progress to shareholders; traders? yea ... sometimes, but not consequentially.
    23 Oct 2012, 06:22 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs